Study S000658

A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

ClinicalTrials.gov record

Registration

Registration: NCT07527910
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 204
Start: 2026-05-22
Primary completion: 2030-03-15
Lead sponsor: Regeneron Pharmaceuticals
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: DRUG:ALN-PNP; DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent change in liver fat [From baseline at week 24]
Percent change in liver fat [From baseline at week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.